Warfarin
- Generic Name
- Warfarin
- Brand Names
- Coumadin, Jantoven
- Drug Type
- Small Molecule
- Chemical Formula
- C19H16O4
- CAS Number
- 81-81-2
- Unique Ingredient Identifier
- 5Q7ZVV76EI
- Background
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ...
- Indication
Indicated for:
1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.
2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.
3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.
...
- Associated Conditions
- Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
- Associated Therapies
- -
Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea
- Conditions
- Interventions
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 64684
- Registration Number
- NCT03572972
- Locations
- 🇰🇷
Korea University Hospital, Seoul, Korea, Republic of
Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis
- Conditions
- Interventions
- First Posted Date
- 2018-06-25
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Hospital Geral Roberto Santos
- Target Recruit Count
- 50
- Registration Number
- NCT03566303
- Locations
- 🇧🇷
Andre Duraes, Salvador, Bahia, Brazil
Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4
- Conditions
- Interventions
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 40
- Registration Number
- NCT03556592
- Locations
- 🇳🇱
LEO Pharma Investigational Site, Leiden, Netherlands
Dabigatran Versus Warfarin With NVAF Who Undergo PCI
- Conditions
- Interventions
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- Shenyang Northern Hospital
- Target Recruit Count
- 1120
- Registration Number
- NCT03536611
- Locations
- 🇨🇳
General Hospital of Northern Theater Command, Shenyang, Liaoning, China
Biological Effect of Warfarin on Pancreatic Cancer
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2021-03-25
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Registration Number
- NCT03536208
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Acute Mesenteric Venous Thrombosis.. in Assiut University Hospital Management Controversies
- Conditions
- Interventions
- First Posted Date
- 2018-03-30
- Last Posted Date
- 2018-03-30
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 30
- Registration Number
- NCT03483207
Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 1512
- Registration Number
- NCT03463317
- Locations
- 🇩🇪
Vivantes Klinik Am Urban, Kardiologie, Berlin, Germany
🇩🇪Charité Universitätsmedizin Berlin, CBF, Kardiologie, Berlin, Germany
🇩🇪Vivantes Klinikum Neukölln, Kardiologie, Berlin, Germany
Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin
- Conditions
- Interventions
- First Posted Date
- 2018-02-08
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- Akcea Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT03426033
- Locations
- 🇨🇦
Clinical Site, Mount Royal, Quebec, Canada
A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 56
- Registration Number
- NCT03363815
- Locations
- 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States
Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16000
- Registration Number
- NCT03359876
- Locations
- 🇺🇸
US Truven MarketScan, Whippany, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.